1,25-dihydroxyvitamin D3 promotes high glucose-induced M1 macrophage switching to M2 via the VDR-PPARγ signaling pathway

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Zhang, Xiaoliang ^a   Zhou, Min ^a   Guo, Yinfeng ^a   Song, Zhixia ^a   Liu, Bicheng ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ARGINASE 1; CALCITRIOL; GLUCOSE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; MANNITOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; CYTOKINE; NOS2 PROTEIN, MOUSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HYPEROSMOLARITY; IMMUNOFLUORESCENCE; MACROPHAGE; MACROPHAGE ACTIVATION; NONHUMAN; PHENOTYPE; POLARIZATION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DIABETIC NEPHROPATHY; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; CALCITRIOL; CYTOKINES; DIABETIC NEPHROPATHIES; GENE EXPRESSION REGULATION; GLUCOSE; INFLAMMATION; MACROPHAGES; MICE; NITRIC OXIDE SYNTHASE TYPE II; PPAR GAMMA; RECEPTORS, CALCITRIOL; SIGNAL TRANSDUCTION;

EID: 84929359317     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/157834     Document Type: Article

References (36)

1. J. M. López-Novoa, C.Martínez-Salgado, A. B. Rodríguez-Peña, andF. J.Hernández, "Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives," Pharmacology &Therapeutics, vol. 128, no. 1, pp. 61-81, 2010.
2. S. D. Ricardo, H. vanGoor, andA.A.Eddy, "Macrophage diversity in renal injury and repair," Journal of Clinical Investigation, vol. 118, no. 11, pp. 3522-3530, 2008.
3. L. Schiffer, R. Bethunaickan, M. Ramanujam et al., "Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis," Journal of Immunology, vol. 180, no. 3, pp. 1938-1947, 2008.
4. V. Vielhauer, O. Kulkarni, C. A. Reichel, and H.-J. Anders, "Targeting the recruitment of monocytes and macrophages in renal disease," Seminars in Nephrology, vol. 30, no. 3, pp. 318-333, 2010.
5. S. Klahr and J. Morrissey, "Obstructive nephropathy and renal fibrosis,"The American Journal of Physiology - Renal Physiology, vol. 283, no. 5, pp. F861-F875, 2002.
6. M. A. Vernon, K. J.Mylonas, and J. Hughes, "Macrophages and renal fibrosis," Seminars in Nephrology, vol. 30, no. 3, pp. 302-317, 2010.
7. H.-J. Anders and M. Ryu, "Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis," Kidney International, vol. 80, no. 9, pp. 915-925, 2011.
8. Y. Wang, Q. Cai, G. Zheng et al., "By homing to the kidney, activated macrophages potently exacerbate renal injury," The American Journal of Pathology, vol. 172, no. 6, pp. 1491-1499, 2008.
9. E. Rigamonti, P. Zordan, C. Sciorati, P. Rovere-Querini, and S. Brunelli, "Macrophage plasticity in skeletal muscle repair," BioMed Research International, vol. 2014, Article ID 560629, 9 pages, 2014.
10. C. Jakubzick, E. S. Choi, S. L. Kunkel, B. H. Joshi, R. K. Puri, andC. M. Hogaboam, "Impact of interleukin-13 responsiveness on the synthetic and proliferative properties of Th1-and Th2-type pulmonary granuloma fibroblasts," American Journal of Pathology, vol. 162, no. 5, pp. 1475-1486, 2003.
11. S. Lee, S. Huen, H. Nishio et al., "Distinct macrophage phenotypes contribute to kidney injury and repair," Journal of the American Society of Nephrology, vol. 22, no. 2, pp. 317-326, 2011.
12. Q. Cao, Y. Wang, D. Zheng et al., "IL-10/TGF-α-modified macrophages induce regulatory T cells and protect against adriamycin nephrosis," Journal of the American Society of Nephrology, vol. 21, no. 6, pp. 933-942, 2010.
13. X. Tan, Y. Li, andY. Liu, "Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy," Journal of the American Society of Nephrology, vol. 17, no. 12, pp. 3382-3393, 2006.
14. Y. Nakayama, S. Ueda, and S. Okuda, "Molecular mechanism underlying the renoprotective action of vitamin D," Circulation Journal, vol. 78, no. 3, pp. 599-600, 2014.
15. Z. Song, Y. Guo, M. Zhou, and X. Zhang, "The PI3K/p-Akt signaling pathway participates in calcitriol ameliorating podocyte injury in DN rats," Metabolism, vol. 63, no. 10, pp. 1324-1333, 2014.
16. X. L. Zhang, Y. F. Guo, Z. X. Song, and M. Zhou, "Vitamin D prevents podocyte injury via regulation of macrophage M1/M2 phenotype in diabetic nephropathy rats," Endocrinology, vol. 155, no. 12, pp. 4939-4950, 2014.
17. M. R. Haussler, G. K. Whitfield, C. A. Haussler et al., "The nuclear vitaminDreceptor: biological andmolecular regulatory properties revealed," Journal of Bone and Mineral Research, vol. 13, no. 3, pp. 325-349, 1998.
18. M. Di Rosa, M. Malaguarnera, F. Nicoletti, and L. Malaguarnera, "Vitamin D3: a helpful immuno-modulator," Immunology, vol. 134, no. 2, pp. 123-139, 2011.
19. C. Mathieu and L. Adorini, "The coming of age of 1,25-dihydroxyvitamin D3 analogs as immunomodulatory agents," Trends in Molecular Medicine, vol. 8, no. 4, pp. 174-179, 2002.
20. J. I. Odegaard, R. R. Ricardo-Gonzalez, M. H. Goforth et al., "Macrophage-specific PPARα controls alternative activation and improves insulin resistance," Nature, vol. 447, no. 7148, pp. 1116-1120, 2007.
21. J. A. Díaz-Gandarilla, C. Osorio-Trujillo, V. I. Hernández-Ramírez, and P. Talamás-Rohana, "PPAR activation induces m1 macrophage polarization via cPLACOX-2 inhibition, activating ros production against LeishmaniaMexicana," BioMed Research International, vol. 2013, Article ID 215283, 13 pages, 2013.
22. T. W. Dunlop, S. Väisänen, C. Frank et al., "The human peroxisome proliferator-activated receptor α gene is a primary target of 1α,25-dihydroxyvitamin D3 and its nuclear receptor," Journal of Molecular Biology, vol. 349, no. 2, pp. 248-260, 2005.
23. F. Alimirah, X. Peng, L. Yuan et al., "Crosstalk between the peroxisome proliferator-activated receptor α (PPARα) and the vitamin D receptor (VDR) in human breast cancer cells: PPARα binds to VDR and inhibits 1α,25-dihydroxyvitamin D3 mediated transactivation," Experimental Cell Research, vol. 318, no. 19, pp. 2490-2497, 2012.
24. P. Sertznig, T. Dunlop, M. Seifert, W. Tilgen, and J. Reichrath, "Cross-talk between vitamin D receptor (VDR)-and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells," Anticancer Research, vol. 29, no. 9, pp. 3647-3658, 2009.
25. P. Sertznig, M. Seifert, W. Tilgen, and J. Reichrath, "Activation of vitamin D receptor (VDR)-and peroxisome proliferatoractivated receptor (PPAR)-signaling pathways through 1,25(OH)(2)D(3) inmelanoma cell lines and other skin-derived cell lines," Dermato-Endocrinology, vol. 1, no. 4, pp. 232-238, 2009.
26. P. Sertznig, M. Seifert, W. Tilgen, and J. Reichrath, "Peroxisome proliferator-activated receptor (PPAR) and vitamin D receptor (VDR) signaling pathways in melanoma cells: promising new therapeutic targets?" The Journal of Steroid Biochemistry and Molecular Biology, vol. 121, no. 1-2, pp. 383-386, 2010.
27. R. E. Gilbert and M. E. Cooper, "The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?" Kidney International, vol. 56, no. 5, pp. 1627-1637, 1999.
28. Y.-M. Sun, Y. Su, J. Li, and L.-F. Wang, "Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy," Biochemical and Biophysical Research Communications, vol. 433, no. 4, pp. 359-361, 2013.
29. F. Chow, E. Ozols, D. J. Nikolic-Paterson, R. C. Atkins, and G. H. Tesch, "Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury," Kidney International, vol. 65, no. 1, pp. 116-128, 2004.
30. D. Nguyen, F. Ping, W. Mu, P. Hill, R. C. Atkins, and S. J. Chadban, "Macrophage accumulation in human progressive diabetic nephropathy," Nephrology, vol. 11, no. 3, pp. 226-231, 2006.
31. X. Zhang, Z. Song, Y. Guo, and M. Zhou, "The novel role of TRPC6 in vitamin D ameliorating podocyte injury in STZinduced diabetic rats,"Molecular and Cellular Biochemistry, vol. 399, no. 1-2, pp. 155-165, 2015.
32. Y. Wang and D. C. Harris, "Macrophages in renal disease," Journal of the American Society of Nephrology, vol. 22, no. 1, pp. 21-27, 2011.
33. Y. Wang, Y. P. Wang, G. Zheng et al., "Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease," Kidney International, vol. 72, no. 3, pp. 290-299, 2007.
34. M. R. Haussler, P. W. Jurutka, M. Mizwicki, and A. W. Norman, "Vitamin D receptor (VDR)-mediated actions of 1α,25(OH)2vitamin D3: genomic and non-genomic mechanisms," Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 25, no. 4, pp. 543-559, 2011.
35. M. Levi, "Nuclear receptors in renal disease," Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1812, no. 8, pp. 1061-1067, 2011.
36. I. Ito, T. Waku, M. Aoki et al., "A nonclassical vitamin D receptor pathway suppresses renal fibrosis," The Journal of Clinical Investigation, vol. 123, no. 11, pp. 4579-4594, 2013.